Patent classifications
C07D213/14
COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR
The present invention provides a novel processes for preparation of methyl 3-(benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyiridine-2-carboxylate using novel intermediates.
PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR
The present invention provides a novel processes for preparation of methyl 3-(benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyiridine-2-carboxylate using novel intermediates.
Oxazolidinones as TarO inhibitors
Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic. ##STR00001##
OXAZOLIDINONES AS TARO INHIBITORS
Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.
##STR00001##
Compound and an Organic Semiconducting Layer, an Organic Electronic Device and a Display or Lighting Device Comprising the Same
The present invention relates to a compound of Formula (I): an organic semiconducting layer comprising the same, an organic electronic device comprising the organic semiconducting layer and a display device or a lighting device comprising the organic electronic device.
Compound and an Organic Semiconducting Layer, an Organic Electronic Device and a Display or Lighting Device Comprising the Same
The present invention relates to a compound of Formula (I): an organic semiconducting layer comprising the same, an organic electronic device comprising the organic semiconducting layer and a display device or a lighting device comprising the organic electronic device.
Oxazolidinones as taro inhibitors
Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic. ##STR00001##
AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula:
##STR00001##
where A, B, R.sub.1, X.sub.1, X.sub.2, and W are described herein.